Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL217 in Advanced Solid Tumors
NCT06859762Phase 1Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of YL217 in solid tumor (advanced stage) (2 arms), sponsored by MediLink Therapeutics. Primary endpoints: Dose-Limiting Toxicity, Adverse Events and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
YL217
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06859762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859762.